Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Measles-mumps-rubella booster and post-COVID-19 immunity: A retrospective cohort study

L. Štěpánek, M. Nakládalová, A. Boriková, D. Horáková, L. Štěpánek, R. Večeřová, P. Sauer

. 2025 ; 57 (-) : 127232. [pub] 20250512

Language English Country Netherlands

Document type Journal Article

E-resources Online Full text

NLK ProQuest Central from 2002-01-01 to 2 months ago
Nursing & Allied Health Database (ProQuest) from 2002-01-01 to 2 months ago
Health & Medicine (ProQuest) from 2002-01-01 to 2 months ago
Family Health Database (ProQuest) from 2002-01-01 to 2 months ago
Health Management Database (ProQuest) from 2002-01-01 to 2 months ago
Public Health Database (ProQuest) from 2002-01-01 to 2 months ago

BACKGROUND: The potential cross-protective effect of measles, mumps, and rubella (MMR) vaccination against coronavirus disease 2019 (COVID-19) is debated. Although immunological studies suggest cross-reactivity between MMR-induced immunity and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), epidemiological evidence remains inconclusive. This study examined the association between an additional MMR dose and both COVID-19 clinical and serological outcomes in an adult cohort with verified pre-pandemic measles immunity. METHODS: In 2019, prior to the COVID-19 pandemic, 3027 healthcare workers from a Czech university hospital underwent measles serology testing. Seronegative individuals were offered a single additional MMR dose. Between 2020 and 2021, 261 individuals from the original sample subsequently contracted COVID-19 and underwent post-infection SARS-CoV-2 immunoglobulin G (IgG) serology testing, having remained unvaccinated against COVID-19 until that time. RESULTS: Among 212 women and 49 men (mean age: 42.7 years), 150 were measles-seropositive (without additional vaccination) and 111 were measles-seronegative but received an additional MMR dose. Following COVID-19, 216 participants (82.8 %) exhibited SARS-CoV-2 IgG seropositivity. No significant relationship was observed between measles immunity or MMR vaccine administration and COVID-19 clinical characteristics. However, individuals who received an additional MMR dose were significantly more likely to develop SARS-CoV-2 IgG seropositivity (88.3 % vs. 78.7 %; p = 0.042). Regression analysis confirmed additional MMR vaccination as an independent predictor of post-COVID-19 seropositivity (odds ratio 1.81, 95 % confidence interval 1.17-2.81, p = 0.008), irrespective of the interval between MMR vaccination and COVID-19 symptom onset. No correlation was found between pre-pandemic measles antibody titers and SARS-CoV-2 antibody levels (r = 0.09, p = 0.246). CONCLUSION: While no protective effect of adult MMR vaccination on COVID-19 clinical outcomes was observed, a significant immunological interaction was identified. These findings align with the concept of trained immunity and warrant further investigation.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015612
003      
CZ-PrNML
005      
20250731091126.0
007      
ta
008      
250708e20250512ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.vaccine.2025.127232 $2 doi
035    __
$a (PubMed)40359811
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Štěpánek, Ladislav $u Department of Occupational Medicine, University Hospital Olomouc, Faculty of Medicine and Dentistry, Palacký University Olomouc, Zdravotníků 248/7, 77900 Olomouc, Czech Republic; Department of Public Health, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 3, 77900 Olomouc, Czech Republic. Electronic address: ladislav.stepanek@upol.cz
245    10
$a Measles-mumps-rubella booster and post-COVID-19 immunity: A retrospective cohort study / $c L. Štěpánek, M. Nakládalová, A. Boriková, D. Horáková, L. Štěpánek, R. Večeřová, P. Sauer
520    9_
$a BACKGROUND: The potential cross-protective effect of measles, mumps, and rubella (MMR) vaccination against coronavirus disease 2019 (COVID-19) is debated. Although immunological studies suggest cross-reactivity between MMR-induced immunity and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), epidemiological evidence remains inconclusive. This study examined the association between an additional MMR dose and both COVID-19 clinical and serological outcomes in an adult cohort with verified pre-pandemic measles immunity. METHODS: In 2019, prior to the COVID-19 pandemic, 3027 healthcare workers from a Czech university hospital underwent measles serology testing. Seronegative individuals were offered a single additional MMR dose. Between 2020 and 2021, 261 individuals from the original sample subsequently contracted COVID-19 and underwent post-infection SARS-CoV-2 immunoglobulin G (IgG) serology testing, having remained unvaccinated against COVID-19 until that time. RESULTS: Among 212 women and 49 men (mean age: 42.7 years), 150 were measles-seropositive (without additional vaccination) and 111 were measles-seronegative but received an additional MMR dose. Following COVID-19, 216 participants (82.8 %) exhibited SARS-CoV-2 IgG seropositivity. No significant relationship was observed between measles immunity or MMR vaccine administration and COVID-19 clinical characteristics. However, individuals who received an additional MMR dose were significantly more likely to develop SARS-CoV-2 IgG seropositivity (88.3 % vs. 78.7 %; p = 0.042). Regression analysis confirmed additional MMR vaccination as an independent predictor of post-COVID-19 seropositivity (odds ratio 1.81, 95 % confidence interval 1.17-2.81, p = 0.008), irrespective of the interval between MMR vaccination and COVID-19 symptom onset. No correlation was found between pre-pandemic measles antibody titers and SARS-CoV-2 antibody levels (r = 0.09, p = 0.246). CONCLUSION: While no protective effect of adult MMR vaccination on COVID-19 clinical outcomes was observed, a significant immunological interaction was identified. These findings align with the concept of trained immunity and warrant further investigation.
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a dospělí $7 D000328
650    12
$a vakcína proti spalničkám, příušnicím a zarděnkám $x imunologie $x aplikace a dávkování $7 D022542
650    12
$a COVID-19 $x imunologie $x prevence a kontrola $x epidemiologie $7 D000086382
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a lidé středního věku $7 D008875
650    _2
$a protilátky virové $x krev $x imunologie $7 D000914
650    12
$a sekundární imunizace $7 D007117
650    _2
$a SARS-CoV-2 $x imunologie $7 D000086402
650    _2
$a imunoglobulin G $x krev $x imunologie $7 D007074
650    _2
$a spalničky $x prevence a kontrola $x imunologie $7 D008457
650    _2
$a příušnice $x prevence a kontrola $7 D009107
650    _2
$a zarděnky $x prevence a kontrola $7 D012409
651    _2
$a Česká republika $x epidemiologie $7 D018153
655    _2
$a časopisecké články $7 D016428
700    1_
$a Nakládalová, Marie $u Department of Occupational Medicine, University Hospital Olomouc, Faculty of Medicine and Dentistry, Palacký University Olomouc, Zdravotníků 248/7, 77900 Olomouc, Czech Republic
700    1_
$a Boriková, Alena $u Department of Occupational Medicine, University Hospital Olomouc, Faculty of Medicine and Dentistry, Palacký University Olomouc, Zdravotníků 248/7, 77900 Olomouc, Czech Republic
700    1_
$a Horáková, Dagmar $u Department of Public Health, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 3, 77900 Olomouc, Czech Republic
700    1_
$a Štěpánek, Lubomír $u Department of Statistics and Probability, Faculty of Informatics and Statistics, Prague University of Economics and Business, Churchill Square 1938/4, 13067 Prague, Czech Republic
700    1_
$a Večeřová, Renata $u Department of Microbiology, University Hospital Olomouc, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 3, 77900 Olomouc, Czech Republic
700    1_
$a Sauer, Pavel $u Department of Microbiology, University Hospital Olomouc, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 3, 77900 Olomouc, Czech Republic
773    0_
$w MED00004631 $t Vaccine $x 1873-2518 $g Roč. 57 (20250512), s. 127232
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40359811 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091120 $b ABA008
999    __
$a ok $b bmc $g 2366460 $s 1252737
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 57 $c - $d 127232 $e 20250512 $i 1873-2518 $m Vaccine $n Vaccine $x MED00004631
LZP    __
$a Pubmed-20250708

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...